IP Library Granted Patent US 10,086,020
Granted Patent B2
US 10,086,020 · App. 15/915,885 · Granted Oct 2, 2018

Compositions comprising bacterial strains

Inventors: Annick Bernalier-Donadille (La Roche Blanc, FR); Laureen Crouzet (Beaumont, FR); Chloe Habouzit (Chamalieres, FR)
Assignee: 4D Pharma PLC
A61K35/74A61K9/19A61K9/48A61P1/10A61P1/12A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,086,020
App. No.
15/915,885
Granted
Oct 2, 2018
Kind
B2
Abstract

The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.

Claims (16)

1. A method of treating diarrhea, constipation, or diarrhea and constipation in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising:

a bacteria strain of Blautia hydrogenotrophica sufficient to treat the diarrhea, constipation, or diarrhea and constipation in the subject; and

a pharmaceutically acceptable excipient, diluent, or carrier,

wherein the bacteria strain comprises a 16S rRNA gene sequence of SEQ ID NO: 5,

and

wherein the administering results in a reduction in the diarrhea, constipation, or diarrhea and constipation in the subject.

2. The method of claim 1 , wherein the bacteria strain is active.

3. The method of claim 1 , wherein the pharmaceutical composition is encapsulated.

4. The method of claim 1 , wherein the pharmaceutical composition is lyophilized.

5. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral delivery.

6. The method of claim 5 , wherein the pharmaceutical composition is enterically coated.

7. The method of claim 1 , wherein the pharmaceutical composition comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU)/g of the bacteria strain with respect to a total weight of the pharmaceutical composition.

8. The method of claim 1 , wherein the subject has diarrhea and constipation.

9. The method of claim 1 , wherein the pharmaceutical composition comprises an amount sufficient to reduce an amount of hydrogen in the breath of the subject as determined by an administration of lactulose followed by a hydrogen breath analysis.

10. The method of claim 1 , wherein the administering comprises providing one or more doses of 1 g, 3 g, 5 g or 10 g of the pharmaceutical composition.

11. The method of claim 1 , wherein at least 50% of the bacteria strain as measured by an amount of colony forming units (CFU) remains viable after about 1 year of storage when the pharmaceutical composition is stored in a closed container at 25° C. at 95% relative humidity.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED
To: CJ BIOSCIENCE, INC.
Reel/Frame 063992/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: OXFORD FINANCE LUXEMBOURG S.A R.L.
To: ARMISTICE CAPITAL MASTER FUND LTD.
Reel/Frame 061806/0371 →
INTELECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 30, 2021
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED; 4D PHARMA CORK LIMITED; 4D PHARMA DELAWARE INC.
To: OXFORD FINANCE LUXEMBOURG S.A R.L.
Reel/Frame 057042/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2018
From: BERNALIER-DONADILLE, ANNICK; CROUZET, LAUREEN; HABOUZIT, CHLOE
To: 4D PHARMA PLC
Reel/Frame 045715/0167 →
Priority Claims (5)
GB 1612190.7 · Jul 13, 2016 · national
GB 1616016.0 · Sep 20, 2016 · national
GB 1616018.6 · Sep 20, 2016 · national
GB 1703548.6 · Mar 6, 2017 · national
GB 1703552.8 · Mar 6, 2017 · national
Continuity (2)
Continuation PCTGB2017052077 · Jul 13, 2017
Related Publication 20180207207A1 · Jul 26, 2018